Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment

키워드

참고문헌 (71)

1. Otte C, "Major depressive disorder", Nat Rev Dis Primers, 2, pp.16065~ (2016)
2. Malhi GS, "Depression", Lancet, 392, pp.2299~2312 (2018)
3. Vos T, "The burden of major depression avoidable by longer-term treatment strategies", Arch Gen Psychiatry, 61, pp.1097~1103 (2004)
4. Lewis G, "Maintenance or discontinuation of antidepressants in primary care", N Engl J Med, 385, pp.1257~1267 (2021)
5. Boschloo L, "The four-year course of major depressive disorder : The role of staging and risk factor determination", Psychother Psychosom, 83, pp.279~288 (2014)
6. Fernandes BS, "Insulin resistance in depression : A large meta-analysis of metabolic parameters and variation", Neurosci Biobehav Rev, 139, pp.104758~ (2022)
7. Penninx BW, "Understanding the somatic consequences of depression : Biological mechanisms and the role of depression symptom profile", BMC Med, 11, pp.129~ (2013)
8. Walker ER, "Mortality in mental disorders and global disease burden implications : A systematic review and meta-analysis", JAMA Psychiatry, 72, pp.334~341 (2015)
9. McAllister-Williams RH, "The identification, assessment and management of difficult-to-treat depression : An international consensus statement", J Affect Disord, 267, pp.264~282 (2020)
10. Hodes GE, "Neuroimmune mechanisms of depression", Nat Neurosci, 18, pp.1386~1393 (2015)
11. Kim JM, "Possible link between serotonin and interleukin 18 on suicidality in patients with acute coronary syndrome", Clin Psychopharmacol Neurosci, 21, pp.386~390 (2023)
12. Reddy PV, "Multiple complement pathway-related proteins might regulate immunopathogenesis of major depressive disorder", Clin Psychopharmacol Neurosci, 21, pp.313~319 (2023)
13. Haapakoski R, "Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder", Brain Behav Immun, 49, pp.206~215 (2015)
14. Choi W, "Interactive effects of serum leptin levels and physical comorbidity on the pharmacotherapeutic response of depressive disorders", Clin Psychopharmacol Neurosci, 20, pp.662~674 (2022)
15. Karimi Z, "Proposed pathway linking respiratory infections with depression", Clin Psychopharmacol Neurosci, 20, pp.199~210 (2022)
16. Liu ST, "The clinical observation of inflammation theory for depression : The initiative of the formosa long COVID multicenter study(FOCuS)", Clin Psychopharmacol Neurosci, 21, pp.10~18 (2023)
17. Vieta E, "Disruptive treatments in psychiatry", Rev Psiquiatr Salud Ment(Engl Ed), 13, pp.1~4 (2020)
18. Köhler-Forsberg O, "Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms : Metaanalysis of clinical trials", Acta Psychiatr Scand, 139, pp.404~419 (2019)
19. Miller AH, "The role of inflammation in depression : From evolutionary imperative to modern treatment target", Nat Rev Immunol, 16, pp.22~34 (2016)
20. Baune BT, "No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression : A 6-week double-blind placebo controlled randomized trial", Eur Neuropsychopharmacol, 53, pp.34~46 (2021)
21. Strumila R, "Null effect of vortioxetine augmentation with celecoxib should not be generalized to other antidepressants", Eur Neuropsychopharmacol, 55, pp.84~85 (2022)
22. Nettis MA, "Minocycline in major depressive disorder : And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders", Brain Behav Immun Health, 17, pp.100335~ (2021)
23. Cai DB, "Minocycline for depressive symptoms : A meta-analysis of randomized, double-blinded, placebo-controlled trials", Psychiatr Q, 91, pp.451~461 (2020)
24. Dean OM, "Adjunctive minocycline treatment for major depressive disorder : A proof of concept trial", Aust N Z J Psychiatry, 51, pp.829~840 (2017)
25. Husain MI, "Minocycline as an adjunct for treatment-resistant depressive symptoms : A pilot randomised placebo-controlled trial", J Psychopharmacol, 31, pp.1166~1175 (2017)
26. Emadi-Kouchak H, "Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients : A double-blind, placebo-controlled, randomized trial", Int Clin Psychopharmacol, 31, pp.20~26 (2016)
27. Savitz JB, "Treatment of bipolar depression with minocycline and", or aspirin : An adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial, 2018, pp.8, 27~
28. Dean OM, "Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder : A double blind, randomised, placebo controlled trial", Clin Psychopharmacol Neurosci, 12, pp.180~188 (2014)
29. Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
30. Hamilton M, "The assessment of anxiety states by rating", Br J Med Psychol, 32, pp.50~55 (1959)
31. Guy W, "ECDEU assessment manual for psychopharmacology-revised", pp.218~222 (1976), US Department of Health, Education, and Welfare Publication (ADM). National Institute of Mental Health. Scientific Research Publishing
32. Morosini PL, "Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale(SOFAS)to assess routine social functioning", Acta Psychiatr Scand, 101, pp.323~329 (2000)
33. Keller MB, "The longitudinal interval follow-up evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies", Arch Gen Psychiatry, 44, pp.540~548 (1987)
34. Endicott J, "Quality of life enjoyment and satisfaction questionnaire : A new measure", Psychopharmacol Bull, 29, pp.321~326 (1993)
35. Sanna L, "Physical comorbidities in men with mood and anxiety disorders : A population-based study", BMC Med, 11, pp.110~ (2013)
36. Soreca I, "The phenomenology of bipolar disorder : What drives the high rate of medical burden and determines long-term prognosis?", Depress Anxiety, 26, pp.73~82 (2009)
37. Magalhães PV, "Illness burden and medical comorbidity in the systematic treatment enhancement program for bipolar disorder", Acta Psychiatr Scand, 125, pp.303~308 (2012)
38. Jakobsen JC, "When and how should multiple imputation be used for handling missing data in randomised clinical trials-a practical guide with flowcharts", BMC Med Res Methodol, 17, pp.162~ (2017)
39. Kraemer HC, "Mediators and moderators of treatment effects in randomized clinical trials", Arch Gen Psychiatry, 59, pp.877~883 (2002)
40. Van Breukelen GJ, "ANCOVA versus change from baseline : More power in randomized studies, more bias in nonrandomized studies", J Clin Epidemiol, 59, pp.920~925 (2006)
41. Leonard B, "Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression", Neurosci Biobehav Rev, 36, pp.764~785 (2012)
42. Egeland M, "Molecular mechanisms in the regulation of adult neurogenesis during stress", Nat Rev Neurosci, 16, pp.189~200 (2015)
43. Schmaal L, "Subcortical brain alterations in major depressive disorder : Findings from the ENIGMA major depressive disorder working group", Mol Psychiatry, 21, pp.806~812 (2016)
44. Salagre E, "Treatment of neurocognitive symptoms in unipolar depression : A systematic review and future perspectives", J Affect Disord, 221, pp.205~221 (2017)
45. Rosenblat JD, "Inflamed moods : A review of the interactions between inflammation and mood disorders", Prog Neuropsychopharmacol Biol Psychiatry, 53, pp.23~34 (2014)
46. Köhler CA, "Peripheral cytokine and chemokine alterations in depression : A meta-analysis of 82 studies", Acta Psychiatr Scand, 135, pp.373~387 (2017)
47. Maes M, "The compensatory immune-regulatory reflex system(CIRS)in depression and bipolar disorder", Mol Neurobiol, 55, pp.8885~8903 (2018)
48. Roman M, "Novel neuroimmunologic therapeutics in depression : A clinical perspective on what we know so far", Brain Behav Immun, 83, pp.7~21 (2020)
49. Marx W, "The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia : A meta-analysis of 101 studies", Mol Psychiatry, 26, pp.4158~4178 (2021)
50. Rojewska E, "Pharmacological inhibition of indoleamine 2, 3-dioxygenase-2 and kynurenine 3-monooxygenase, enzymes of the kynurenine pathway, significantly diminishes neuropathic pain in a rat model", Front Pharmacol, 9, pp.724~ (2018)
51. Hashimoto K, "A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells : Translation initiation factor eIF4AI", PLoS One, 5, pp.e15430~ (2010)
52. Stephens JW, "The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease", Atherosclerosis, 202, pp.321~329 (2009)
53. Kapczinski F, "A systemic toxicity index developed to assess peripheral changes in mood episodes", Mol Psychiatry, 15, pp.784~786 (2010)
54. Malik S, "Biomarkers of major depressive disorder : Knowing is half the battle", Clin Psychopharmacol Neurosci, 19, pp.12~25 (2021)
55. McEwen BS, "Mood disorders and allostatic load", Biol Psychiatry, 54, pp.200~207 (2003)
56. Grande I, "Mediators of allostasis and systemic toxicity in bipolar disorder", Physiol Behav, 106, pp.46~50 (2012)
57. Cheng S, "Minocycline reduces neuroinflammation but does not ameliorate neuron loss in a mouse model of neurodegeneration", Sci Rep, 5, pp.10535~ (2015)
58. Bassett B, "Minocycline alleviates depression-like symptoms by rescuing decrease in neurogenesis in dorsal hippocampus via blocking microglia activation", phagocytosis, 2021, pp.91, 519~530
59. Camargos QM, "Minocycline treatment prevents depression and anxiety-like behaviors and promotes neuroprotection after experimental ischemic stroke", Brain Res Bull, 155, pp.1~10 (2020)
60. Malhotra K, "Minocycline for acute stroke treatment : A systematic review and meta-analysis of randomized clinical trials", J Neurol, 265, pp.1871~1879 (2018)
61. Wang B, "Minocycline prevents the depressive-like behavior through inhibiting the release of HMGB1 from microglia and neurons", Brain Behav Immun, 88, pp.132~143 (2020)
62. Lee JS, "Social isolation-related depression accelerates ethanol intake via microglia-derived neuroinflammation", Sci Adv, 7, pp.eabj3400~ (2021)
63. Ahmed A, "Minocycline inhibits sleep deprivation-induced aberrant microglial activation and Keap1-Nrf2 expression in mouse hippocampus", Brain Res Bull, 174, pp.41~52 (2021)
64. Sakurai M, "Minocycline prevents depression-like behavior in streptozotocin-induced diabetic mice", Neuropathology, 41, pp.109~117 (2021)
65. Morris G, "Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders", Neurosci Biobehav Rev, 107, pp.862~882 (2019)
66. Berk M, "Neuroprogression : Pathways to progressive brain changes in bipolar disorder", Int J Neuropsychopharmacol, 12, pp.441~445 (2009)
67. Enache D, "Markers of central inflammation in major depressive disorder : A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue", Brain Behav Immun, 81, pp.24~40 (2019)
68. Nettis MA, "Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation : Results from a double-blind randomised clinical trial", Neuropsychopharmacology, 46, pp.939~948 (2021)
69. Hasebe K, "Exploring interleukin-6, lipopolysaccharidebinding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression", Acta Neuropsychiatr, 34, pp.220~227 (2022)
70. Salagre E, "Precision psychiatry : Complex problems require complex solutions", Eur Neuropsychopharmacol, 52, pp.94~95 (2021)
71. Berk M, "Anti-inflammatory treatment of bipolar depression : Promise and disappointment", Lancet Psychiatry, 7, pp.467~468 (2020)

관련 논문AI추천